8 results about "In vitro study" patented technology

This invention relates to the field of organoid disease models, and discloses a method for constructing a human brain organoid model of early-onset Alzheimer's disease (AD) and its applications. This invention introduces [a specific technology] into human embryonic stem cell lines through single-base editing and lead editing techniques. PSEN1 ΔE9、 PSEN1 M146V and APP Human embryonic stem cell lines carrying four familial pathogenic gene mutations (K670N and M671L) were constructed and induced to differentiate into Alzheimer's disease (AD) brain organoids. The AD brain organoid model established by this invention exhibited tau phosphorylation pathological phenotypes as early as 20 days and Aβ-related phenotypes as early as 40 days, with increased total Aβ, decreased Aβ42 / Aβ40 ratio, and simultaneous aggravation of Aβ-Tau pathology. This represents a complex neurodegenerative pathological model where multiple mutations synergistically regulate Aβ production and tau phosphorylation, which is highly valuable for understanding and studying early-onset familial AD. This invention provides a human brain organoid model for in vitro AD studies and offers a tool for studying the pathological mechanisms of AD and screening drugs.

The application discloses a human vagina micro-ecological in-vitro model and a construction method and application thereof, and relates to the technical field of medicines.The application discloses a human vagina micro-ecological in-vitro model and a construction method and application thereof.Firstly, a mixed cell group of the vaginal epithelium containing a complete cell lineage and capable of long-term subculture is successfully established, a technical bottleneck that primary vaginal epithelial cells are difficult to expand is solved, and ideal seed cells are provided for model construction.Secondly, a highly-bionic vaginal mucosa model having a tight connection structure, rich layers and an orderly arrangement is constructed, and the physiological barrier and immune regulation functions of the vaginal mucosa are truly simulated.Finally, by introducing lactobacillus symbiosis and confirming the response to estrogen, a multi-element in-vitro research model integrating the anatomical structure of the vagina, resident flora, local immunity and endocrine regulation is constructed, and a reliable technical platform is provided for in-depth exploration of the mechanism of vaginal micro-ecological disorder and efficient screening of related drugs.

This invention belongs to the medical field and provides a human trophoblastic stem cell line derived from complete hydatidiform mole and its applications. The human trophoblastic stem cell line, with accession number CGMCC No. C2024411, can be induced to differentiate into syncytiotrophoblast and extravillous trophoblast, mimicking the differentiation and developmental defects of the trophoblastic lineage in hydatidiform mole. It can be used as an in vitro research model for complete hydatidiform mole and has broad application prospects in drug target research and genetic studies.

The application provides a trophoblast organ-on-chip system for simulating a maternal-fetal interface of a systemic lupus erythematosus model based on an organ chip and a construction method thereof, the system taking an organ chip as a carrier and comprising three core parts of a trophoblast organ, an endometrial chip and an SLE disease model. The application completes separation culture and characterization of the trophoblast organ, multi-cell co-culture construction and characterization of the endometrial chip, and then constructs a pathological model, and the three parts cooperatively form a three-dimensional maternal-fetal interface. The system can clearly observe the dynamic process of the trophoblast organ invading the endometrial chip, can detect the continuous secretion of hCG and SLE-related inflammatory factors, and breaks through the defects of the prior art model, such as low authenticity, inability to dynamically observe, single detection dimension and lack of standardization, and has both physiological and pathological adhesion and experimental repeatability, can multi-dimensionally characterize the cell phenotype and function of the maternal-fetal interface, and provides an in-vitro research platform for the pathological mechanism research of the SLE pregnancy-related abnormal maternal-fetal interface.

The application belongs to the technical field of antitumor drugs, and particularly relates to a nanofiber hydrogel for synergistic antitumor sonodynamic / chemodynamic therapy, a preparation method and application thereof, synthesis of Nap-Pept, preparation of Nap-Pept / Fe 3+ / Cur nanogel, under ultrasonic conditions, synergistic sonodynamic therapy of a traditional Chinese medicine sonosensitizer Cur and Fe 3+ mediated chemodynamic therapy, triggering immunogenic death of cancer cells by increasing ROS levels of B16F10 cells and then damaging mitochondrial function. Nap-Pept / Fe 3+ / Cur@US promotes expression of the immune-related factor calnexin, release of high mobility group protein 1 and maturation of dendritic cells to kill tumor cells, thereby exerting an antitumor effect. In vivo and in vitro studies show that the anticancer effect of the combined sonodynamic and chemodynamic therapy is superior to that of single therapy, achieving the purpose of precise and efficient anti-melanoma.

This invention provides the application of a TPE-Ketoalkyne probe in the preparation of a product specifically distinguishing urate and hydroxyapatite crystals. This product comprises a TPE-Ketoalkyne probe that specifically binds to urate crystals. This invention optimizes rapid imaging technology for MSU crystals in in vitro studies using the TPE-Ketoalkyne probe. The imaging effect is comparable to that of birefringent MSU crystals detected by clinical professionals using CPLM, especially in differentiating between different types of crystalline arthritis caused by MSU and HAP crystals. The fluorescence produced by the TPE-Ketoalkyne probe differs from ordinary fluorescence; it is non-quenchable and can be monitored for extended periods. This provides not only a good platform for basic research related to gout but also a new auxiliary means for clinical detection of gout.

The invention belongs to the technical field of transplanted vascular remodeling diagnosis and treatment, and discloses application of a reagent for inhibiting or detecting Fasn and a medicine for preventing and / or treating transplanted vascular remodeling. Experimental research discovers that a group of novel macrophages capable of self-synthesizing lipid exist in the transplantation blood vessel reconstruction process, and Fasn is remarkably activated, so that intracellular lipid accumulation is caused, and the macrophages are promoted to be converted into foam cells. In-vitro studies show that by inhibiting the activity of the Fasn enzyme or down-regulating the expression of the Fasn enzyme, the transformation of macrophages to foam cells can be obviously inhibited, and the synthesis of lipid in cells can be reduced. Based on the discovery, the nucleic acid medicine constructed by adopting the siRNA is used for treating and / or relieving transplanted vascular remodeling. In-vivo experiments further prove that the nucleic acid medicine can remarkably inhibit intimal hyperplasia of transplanted blood vessels and reduce the neointimal / medial membrane ratio, so that the therapeutic effect is achieved. The method has a good application prospect.

The application provides a hemoglobin cascade response nano vesicle and a preparation method and application thereof, and belongs to the technical field of biological medicine. The first hemoglobin response nano vesicle (DecAS-PC@NM) is designed, and disease-specific treatment is realized through cascade reaction of two functional phospholipids. First, hemoglobin activates artemisinin-modified phospholipid (A-PC) to generate active oxygen, the active oxygen oxidizes the sulfide structure in another phospholipid (S-PC), and the transformation from hydrophilicity to hydrophobicity is caused, so that the vesicle is disintegrated. Through co-assembly with neutrophil membranes, the chemotaxis to inflammatory sites is further enhanced. In vitro studies show that DecAS-PC@NM has unique hemoglobin responsiveness, and in vivo data emphasize its targeting to ischemic cores and significant therapeutic effect. This innovative hemoglobin-triggered phospholipid cascade reaction provides a promising strategy for the treatment of myocardial ischemia-reperfusion injury.